VSV. N. Semykin

V. N. Semykin

*This is an algorithmically generated author record based on publicly available information.

V. N. Semykin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resolution of the VII Annual International Scientific and Practical Conference «RWD/RWE. Possible and Real», 2026

    by A. S. Kolbin, D. Yu. Belousov, Ph. V. Gorkavenko, M. А. Borzova, T. A. Usmanova, V. А. Reznik, V. N. Semykin, A. V. Ivanov, А. С. Колбин, Д. Ю. Белоусов, et al.

    The paper presents the resolution of the VII Annual Scientific and Practical Conference with International Participation “Real Clinical Practice. Possible and Real” (Moscow, September 24, 2026), organized by leading professional associations. The document summarizes discussions on the implementation of real-world data and real-world evidence (RWD/RWE) in Russia and the EAEU. It systematizes regulatory and legal barriers in medicinal product regulation, health technology assessment, clinical guideline development, innovative drug provision models, healthcare information systems and registries, and personal data protection and processing. Proposals are formulated to improve legislation, including clarification of the concepts of de-identification and anonymization, broader access to de-identified data, consideration of RWD/RWE in comprehensive drug assessment and list formation, development of interoperability and health data exchange standards (HL7 FHIR), and harmonization at the EAEU level. The resolution also highlights interagency and expert collaboration and the involvement of patient communities.

  • Open Access

    Resolution of the VI Annual International Scientific and Practical Conference "RWD/RWE. Possible and Real"

    by A. S. Kolbin, V. V. Kalinichenko, D. Yu. Belousov, T. A. Usmanova, V. N. Semykin, A. V. Ivanov

    This article presents the outcomes of the VI Annual Scientific and Practical Conference with international participation "RWD/RWE. Possible and Real", which focused on the use of Real-World Data (RWD) and Real-World Evidence (RWE) in healthcare. The event facilitated a comprehensive analysis of the current state of RWD/RWE regulatory frameworks, methodological approaches, and practical applications in the Russian Federation and the Eurasian Economic Union (EAEU). Key systemic limitations were identified, including gaps in legislation, the lack of standardized methods for data collection and analysis, interoperability issues of information systems, and challenges related to confidentiality and personal data processing. A set of specific proposals and recommendations aimed at improving the regulatory framework, developing in- frastructure for working with RWD, integrating such data into health technology assessment processes, developing clinical guidelines, and implementing innovative drug supply models. Harmonizing approaches at the EAEU level, data standardization, and creating secure mechanisms for researchers and developers to access anonymized medical information are of particular importance. The resolution materials are intended for legislative and executive authorities, regulators, medical and scientific organizations, pharmaceutical industry representatives, and patient communities.


  • Open Access

    Maintaining patient registries, on the basis of which regulatory authorities can make decisions regarding medicines

    by A. V. Ivanov, V. N. Semykin

    The use of data and evidence from real clinical practice (RWD / RWE) is becoming more and more relevant to the healthcare system when making critical decisions in the field of drug circulation regulation, as well as making decisions on the inclusion or non-inclusion of a drug in government funding programs.This article discusses the role of clinical registries as one of the most important sources of RWD / RWE. Definitions of terminology are given, and various types of registers are described according to the type of information collected, methods of its collection, storage, and processing. It also shows the possibility of using registers in decision-making, describes the mechanisms for consolidating information from various types of registers, as well as obtaining data for analysis from other sources, shows the importance of correct collection and validation of data collected in the register.The article also briefly describes the local experience in the development, implementation, and maintenance of registers on the example of a number of disorders.It was prepared using guidelines prepared by the Office of Medical Policy of the Center for Drug Evaluation and Research in collaboration with the Center for Biological Evaluation and Research and the US Food and Drug Administration»s Center of Excellence in Oncology.